canertinib dihydrochloride

Drug Overview

Canertinib dihydrochloride (often referred to in medical research by its lab code, CI-1033) is an experimental cancer medicine. It belongs to a modern group of cancer treatments called Targeted Therapies or “Smart Drugs.” Unlike standard chemotherapy that attacks all fast-growing cells in the body, targeted therapies are designed to seek out and block specific signals that only cancer cells use to grow and spread.

While the science behind canertinib is highly advanced, it is currently an investigational drug. This means it is not available at local pharmacies and was only available to patients participating in clinical research trials.

• Generic Name: Canertinib dihydrochloride (CI-1033)
• US Brand Names: None (Currently an Investigational Agent)
• Drug Class: Pan-ErbB Irreversible Tyrosine Kinase Inhibitor (Targeted Therapy)
• Route of Administration: Oral (taken by mouth as a capsule or tablet)
• FDA Approval Status: Not FDA Approved. It is an investigational drug, and its major commercial clinical trials have been largely discontinued.

What Is It and How Does It Work? (Mechanism of Action)

Canertinib is a Targeted Therapy designed to act as a permanent roadblock inside cancer cells. To understand how it works, we must look at how cells communicate.

On the outside of many cells, there are “receiver antennas” called the ErbB family (which includes well-known receptors like EGFR and HER2). When the body needs cells to grow or heal, it sends chemical messengers to these antennas. Once the message is received, the antenna activates an internal engine called a “tyrosine kinase,” which tells the cell to divide. In many breast and lung cancers, these antennas are mutated or there are too many of them, meaning the “grow” signal is stuck in the “ON” position.

At the molecular level, canertinib dihydrochloride is unique because it is a “pan-ErbB” inhibitor. This means it does not just block one antenna; it blocks all four members of the ErbB family (HER1, HER2, HER3, and HER4).

1. The Lock: The drug enters the cancer cell and finds the ATP-binding pocket (the ignition switch for the cellular engine).
2. Permanent Bonding: Unlike older smart drugs that attach and fall off, canertinib binds irreversibly. It permanently glues itself to the switch.
3. Cell Death: Because the antennas are permanently disabled, the cancer cell can no longer activate its internal survival pathways (specifically the PI3K/Akt and MAPK signaling pathways). Without these signals, the cancer cell stops dividing and triggers a natural self-destruct process called apoptosis.

FDA Approved Clinical Indications

Because canertinib dihydrochloride is an experimental drug, it does not currently have any official FDA-approved uses for the general public.

Oncological Uses (Investigational)

Historically, researchers studied this medicine in clinical trials for:

• Advanced Non-Small Cell Lung Cancer (NSCLC).
• Metastatic Breast Cancer.
• Advanced Ovarian Cancer.

Non-Oncological Uses

• There are no FDA-approved or investigational non-oncological uses for this drug. It was developed strictly for cancer treatment.

Dosage and Administration Protocols

Because canertinib is an investigational drug, there is no single, commercially available prescription dose. The dosing below reflects the protocols that were used during its Phase 1 and Phase 2 clinical trials.

• 
  Renal and Hepatic Insufficiency: Because the drug did not complete its final testing phases for commercial use, exact rules for adjusting the dose for kidney (renal) or liver (hepatic) disease were never fully finalized. In clinical trials, patients with severe liver or kidney problems were generally excluded to ensure their safety.

Clinical Efficacy and Research Results

While the science behind canertinib’s irreversible binding was a major breakthrough, the actual clinical trial results in humans were challenging. Recent oncology reviews (2020-2025) studying the history of pan-ErbB inhibitors note why drugs like canertinib did not move forward to FDA approval.

• Response Rates: In Phase 2 trials for advanced breast and lung cancers, the objective response rate (the percentage of patients whose tumors shrank significantly) was very low, often under 10%.
• Effects on Disease Progression: For most patients, the drug did not significantly extend the time before the cancer started growing again (Progression-Free Survival) compared to other available treatments.
• Toxicity vs. Benefit: The major barrier for canertinib was that it blocked normal, healthy EGFR antennas in the skin and gut just as strongly as the cancer antennas. This caused extreme side effects. Because the side effects were very hard on patients and the tumor shrinkage was minimal, the manufacturer decided to halt its commercial development. The data gathered from canertinib, however, helped scientists invent safer, newer-generation irreversible inhibitors (like afatinib and osimertinib) that are used today.

Safety Profile and Side Effects

Because canertinib blocks receptors that are also found in healthy skin and digestive organs, it caused very tough side effects for patients in clinical trials. Because it is not an FDA-approved medication, it does not carry a formal “Black Box Warning.”

Common Side Effects (>10%)

• Severe Diarrhea: This was the most common and difficult side effect, affecting the vast majority of patients.
• Skin Rash: A severe, acne-like rash on the face, chest, and back.
• Nausea and Vomiting: Stomach upset and loss of appetite.
• Stomatitis: Painful mouth sores and throat ulcers.
• Fatigue: Feeling unusually exhausted.

Serious Adverse Events

• Dehydration and Kidney Injury: Severe, uncontrolled diarrhea often led to dangerous dehydration, which could hurt the kidneys.
• Pneumonitis: Rare but severe inflammation of the lungs, causing coughing and shortness of breath.
• Hepatotoxicity: Elevated liver enzymes, indicating stress on the liver.

Management Strategies

• For Diarrhea: Trial doctors required patients to immediately take strong anti-diarrheal medicines (like loperamide) at the very first sign of loose stools and to drink high-electrolyte fluids.
• For Skin Rash: Doctors prescribed special steroid creams and oral antibiotics to soothe the skin and prevent infection. Alcohol-based skin products were strictly avoided.

Research Areas

While canertinib is no longer being actively developed as a daily pill for patients, it remains an incredibly important tool in laboratory research. Scientists currently use canertinib in laboratory models to study acquired drug resistance. By observing how cancer cells react to this powerful, irreversible glue, researchers are learning how to design the “next generation” of targeted therapies. There is also ongoing laboratory research combining pan-ErbB inhibitors with modern immunotherapy to see if blocking these antennas can make cancer cells more visible to the body’s immune system.

Patient Management and Practical Recommendations

(Note: Because this drug’s clinical trials have largely ended, these recommendations apply generally to patients who took it historically or who are taking similar investigational pan-ErbB inhibitors).

Pre-Treatment Tests to be Performed

• Comprehensive Metabolic Panel (CMP): To thoroughly check liver and kidney function, and baseline hydration levels (electrolytes).
• Complete Blood Count (CBC): To ensure red and white blood cells are at safe levels.
• Tumor Genetic Testing: To confirm the tumor actually relies on the ErbB/EGFR pathways.

Precautions During Treatment

• Dehydration Risk: Patients had to monitor their daily bowel movements closely. Severe diarrhea can become life-threatening if fluids are not replaced quickly.
• Sun Exposure: The drug made the skin extremely sensitive to the sun, making severe sunburns and rashes worse.

“Do’s and Don’ts” list

• DO drink plenty of water and electrolyte drinks daily.
• DO use a thick, alcohol-free moisturizer and wear high-SPF sunscreen every time you go outside.
• DO call your trial nurse immediately if you have more than 4 loose bowel movements in a single day.
• DON’T take over-the-counter acne medicines for the drug-related rash; they will dry out the skin and make the pain worse.
• DON’T start any new vitamins or herbal supplements without checking with your research doctor, as they might interfere with how the drug is processed in the liver.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Canertinib dihydrochloride (CI-1033) is an investigational product whose clinical development has been largely discontinued; it is not approved by the FDA for the treatment, cure, or prevention of any disease. Treatment protocols, dosages, and side effects vary by individual and by specific clinical trial guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, treatment options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.